Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%

Why did OPEC+ increase oil output again? How will Trump’s steel tariffs affect grocery prices? What caused Tesla stock to surge despite business slump? Why was NASA administrator nominee Isaacman withdrawn? How is AI impacting job markets and company hiring? What’s behind the rise in US steel and aluminum tariffs? Why is United Airlines calling the budget airline model dead?

Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%

benzinga.com/markets/biotech/25/05/45703024/pfizer-reports-survival-gains-in-colorectal-cancer-study-combo-therapy-cuts-death-risk-by-over-50

Zinger Key Points
- BRAFTOVI regimen showed a 51% reduced risk of death vs. standard chemo (HR 0.49).
- Median survival with BRAFTOVI combo reached 30.3 months vs. 15.1 months for chemo.
- Get stock picks, daily rankings, and pro-level trading tools in one powerful platform—Memorial Day…

This story appeared on benzinga.com, 2025-05-30 19:10:36.